# CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

> **NCT05585814** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05585814
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585814, "CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT05585814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*